FTC pauses OptumRx insulin case to weigh proposed consent agreement
The Federal Trade Commission withdrew its insulin pricing case against UnitedHealth's OptumRx and its affiliate Emisar from adjudication to consider a proposed consent agreement. The agreement has been approved by the directors of the FTC's competition and consumer protection bureaus but still requires Commission approval, and its terms have not been disclosed.
The Federal Trade Commission has paused its administrative case against OptumRx, the pharmacy benefit manager owned by UnitedHealth Group, and its group purchasing affiliate Emisar Pharma Services, to consider a proposed consent agreement, according to an order released on June 12, 2026. The order said the agreement would resolve the claims against the Optum respondents in their entirety if approved by Commission leadership. No financial terms or conduct remedies have been disclosed.
The FTC filed its administrative complaint in September 2024 against the three largest PBMs — Caremark Rx, Express Scripts and OptumRx — and their affiliated group purchasing organisations, alleging violations of Section 5 of the FTC Act. The agency alleged that the companies built a system that rewarded high list prices by favouring drugs with larger manufacturer rebates on their formularies, pushing insulin makers to compete on rebate size rather than net price and shifting costs onto patients whose out-of-pocket payments are tied to list prices. The proposed Optum agreement has been approved by the directors of the FTC's Bureau of Competition and Bureau of Consumer Protection.
An Optum spokesperson told Fierce Healthcare that the company has long worked to make insulin more affordable and that members of its health plan customers pay an average of $12 per month for insulin. OptumRx had also announced a commitment in the preceding month to disclose drug costs as products move through the supply chain.
The development leaves all three of the largest PBMs — which together handle roughly 80 per cent of US prescriptions — on course to resolve the FTC case through negotiated settlements rather than litigated findings. Express Scripts settled in February 2026 and Caremark reached a proposed consent order in March. The settlements coincide with PBM reforms passed by Congress earlier this year requiring rebate pass-through and delinking PBM fees from list prices in Medicare Part D.
As of July 2026, the specific terms of the Optum agreement had still not been released. The proposed consent order must be accepted by the Commission and placed on the public record for comment before it can be finalised.
Cite this report
The Precedent. "FTC pauses OptumRx insulin case to weigh proposed consent agreement." September 7, 2026. https://theprecedent.org/article/ftc-pauses-optumrx-insulin-case-to-weigh-proposed-consent-agreement
